Advancement of Hyperimmune candidates against select pathogens from the Antibody Therapeutics Business Unit’s Lead Generation Program

At Emergent BioSolutions our vision is to “Protect and Enhance Life”. The Antibody Therapeutics Business Unit focuses on applying immunotherapies to prevent and treat human infectious diseases. This includes finding effective strategies to meet existing and emerging threats to public health and intentional biothreats. As part of these efforts the Lead Generation Program was created to address bacterial, viral and fungal pathogens. MiTacs interns will play a role in these efforts by further strengthening ties between academia and industry, applying new methods and innovations, alongside proven technologies to advance lead candidates towards clinical evaluation and licensure.

Faculty Supervisor:

Sean McKenna

Student:

Amit Koul

Partner:

Emergent BioSolutions

Discipline:

Chemistry

Sector:

Pharmaceuticals

University:

University of Manitoba